论文部分内容阅读
1型糖尿病(T1DM)起病早,一半以上患者可伴有至少一种微血管并发症。T1DM微血管并发症涉及眼、肾、神经等多个重要器官,发病机制复杂。中国T1DM人群庞大,给T1DM及其微血管并发症的防治工作带来巨大挑战。T1DM微血管并发症的治疗除了控制血糖外,还包括控制血压、血脂,以及针对微血管并发症的专项治疗。近年来随着医学技术的发展,干细胞治疗、免疫治疗与基因治疗等新兴技术给T1DM微血管并发症的诊疗带来曙光。
Early onset of type 1 diabetes (T1DM) affects more than half of at least one microvascular complication. T1DM microvascular complications involving the eye, kidney, nerve and other important organs, the pathogenesis is complicated. The huge population of T1DM in China poses a great challenge to the prevention and treatment of T1DM and its microvascular complications. T1DM microvascular complications in addition to controlling blood sugar control, but also includes the control of blood pressure, blood lipids, as well as for microvascular complications of special treatment. In recent years, with the development of medical technology, emerging technologies such as stem cell therapy, immunotherapy and gene therapy bring dawn to the diagnosis and treatment of T1DM microvascular complications.